Papapetropoulos Spiridon, Adi Nikhil, Shehadeh Lina, Bishopric Nanette, Singer Carlos, Argyriou Andreas A, Chroni Elizabeth
Department of Neurology, University of Miami, Miller School of Medicine, Miami, Florida 33136, USA.
J Clin Neurosci. 2008 Sep;15(9):1027-30. doi: 10.1016/j.jocn.2007.08.013. Epub 2008 Jul 9.
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene, especially the G2019S mutation, have been identified as a common cause of Parkinson's disease in southern European and other Mediterranean populations (Iberians, Ashkenazi Jews and North African Arabs). Owing to the geographic and historic vicinity of Greece with areas of high prevalence of LRRK2 mutations we studied the frequency of the G2019S mutation in a well characterized cohort of familial and sporadic Parkinson's disease patients of Greek origin from mainland Greece. The prevalence of the LRRK2 R1441C mutation and the G2385R Asian polymorphism was also determined. We identified no patients with any of the studied mutations/polymorphisms. Very low prevalence of the LRRK2 G2019S mutation has been reported in other southern European populations. LRRK2 mutations appear to be limited in certain populations and differing ancestry and founder effects may explain the reported variability. Accurate estimations of the frequency and penetrance of different LRRK2 mutations are essential for correct and cost-efficient use of genetic testing and proper genetic counseling of patients with Parkinson's disease.
富含亮氨酸重复激酶2(LRRK2)基因的突变,尤其是G2019S突变,已被确定为南欧和其他地中海人群(伊比利亚人、阿什肯纳兹犹太人及北非阿拉伯人)帕金森病的常见病因。由于希腊在地理和历史上与LRRK2突变高发地区相邻,我们研究了来自希腊大陆、具有明确特征的希腊裔家族性和散发性帕金森病患者队列中G2019S突变的频率。同时也测定了LRRK2基因R1441C突变和G2385R亚洲多态性的发生率。我们未发现携带任何所研究突变/多态性的患者。其他南欧人群中也报道了LRRK2基因G2019S突变的极低发生率。LRRK2突变似乎局限于某些人群,不同的祖先和奠基者效应可能解释了所报道的变异性。准确估计不同LRRK2突变的频率和外显率对于正确且经济高效地使用基因检测以及为帕金森病患者提供恰当的遗传咨询至关重要。